Elite Pharmaceuticals Inc (ELTP)

[lasers]

Best to read the 10-Q and understand GAAP derivative losses comparison due to Elite's PPS rise from $0.07 at the beginning of the quarter to $0.12 at the end of the quarter.

Change in 3 months fair value of warrant derivatives -$6,129,579

Change in 3 months fair value of preferred share derivatives -$2,565,495

Please note that the Company’s other income/(expenses) are significantly influenced by the fluctuations in the fair value of outstanding preferred share and warrant derivatives, and that such fair values strongly correlate to and vary inversely with the market share price of the Company’s Common Stock.

During the quarter ended September 30, 2013, the closing price of the Company’s Common Stock rose from $0.07 at the beginning of the quarter to $0.12 at the end of the quarter, as compared to a decrease in the closing price of the Company Common’s from $0.13 to $0.12 occurring in the comparable period of the prior year.

http://www.sec.gov/Archives/edgar/data/1053369/000114420413061851/v359288_10q.htm